|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3742-3750.
Prepublished online as a Blood First Edition Paper on January 10, 2008; DOI 10.1182/blood-2007-05-091504.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5
Bing Z. Carter1,
Duncan H. Mak1,
Wendy D. Schober1,
Martin F. Dietrich1,
Clemencia Pinilla2,
Lyubomir T. Vassilev3,
John C. Reed4, and
Michael Andreeff1
1 The University of Texas M. D. Anderson Cancer Center, Houston;
2 Torrey Pines Institute for Molecular Studies, La Jolla, CA;
3 Roche Pharmaceuticals, Nutley, NJ; and
4 Burnham Institute for Medical Research, La Jolla, CA
Acute myeloid leukemia (AML) cells are relatively resistant to tumor necrosis factor –related apoptosis-inducing ligand (TRAIL). We previously reported that triptolide, a potent anticancer agent from a Chinese herb, decreases XIAP in leukemic cells. We evaluated the combination of triptolide and TRAIL and found synergistic promotion of apoptosis in AML cells. XIAP-overexpressing U937 cells (U937XIAP) were more resistant to TRAIL than U937neo cells, and inhibition of XIAP with the small-molecule inhibitor 1396-11 enhanced TRAIL-induced apoptosis, implying XIAP as a resistance factor in AML. Furthermore, triptolide increased DR5 levels in OCI-AML3, while the DR5 increase was blunted in p53-knockdown OCI-AML3 and p53-mutated U937 cells, confirming a role for p53 in the regulation of DR5. In support of this finding, disruption of MDM2-p53 binding with subsequent increase in p53 levels by nutlin3a increased DR5 levels and sensitized OCI-AML3 cells to TRAIL. The combination of 1396-11 plus nutlin3a plus TRAIL was more effective than either the 1396-11 and TRAIL or nutlin3a and TRAIL combinations in OCI-AML3 cells, further supporting the role of triptolide as a sensitizer to TRAILinduced apoptosis in part by independent modulation of XIAP expression and p53 signaling. Thus, the combination of triptolide and TRAIL may provide a novel strategy for treating AML by overcoming critical mechanisms of apoptosis resistance.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S Ghavami, M Hashemi, S R Ande, B Yeganeh, W Xiao, M Eshraghi, C J Bus, K Kadkhoda, E Wiechec, A J Halayko, et al.
Apoptosis and cancer: mutations within caspase genes
J. Med. Genet.,
August 1, 2009;
46(8):
497 - 510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wang, R. Qi, N. Li, Z. Wang, H. An, Q. Zhang, Y. Yu, and X. Cao
Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression
J. Biol. Chem.,
June 12, 2009;
284(24):
16183 - 16190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gobbi, P. Mirandola, C. Carubbi, C. Micheloni, C. Malinverno, P. Lunghi, A. Bonati, and M. Vitale
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation
Blood,
March 26, 2009;
113(13):
3080 - 3087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. Tazzari, G. Tabellini, F. Ricci, V. Papa, R. Bortul, F. Chiarini, C. Evangelisti, G. Martinelli, A. Bontadini, L. Cocco, et al.
Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells
Cancer Res.,
November 15, 2008;
68(22):
9394 - 9403.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|